Puma Biotechnology | PBYI - الأصول





الأصول تغيير تاريخ
Agios Pharmaceuticals USD 1.11B 76.57M 2026-06
Alnylam Pharmaceuticals USD 5.56B 429.22M 2026-06
Amgen USD 95.64B 3.14B 2026-06
Biogen USD 32.09B 2.6B 2026-06
BioMarin Pharmaceutical USD 11.72B 3.13B 2026-06
Daiichi Sankyo JPY 4.11T 109.16B 2026-06
Exelixis USD 2.49B 99.36M 2026-06
Gilead Sciences USD 49.36B 6.92B 2026-06
Glaxosmithkline GBP 62.87B 19.47B 2026-03
Incyte USD 7.87B 533.53M 2026-06
MacroGenics USD 345.41M 127.54M 2026-06
Moderna USD 10.96B 527M 2026-06
Novartis USD 122.03B 3.5B 2026-06
Pfizer USD 201.13B 6.49B 2026-06
PTC Therapeutics USD 3.25B 381.37M 2026-06
Puma Biotechnology USD 202.86M 7.95M 2025-09
Regeneron Pharmaceuticals USD 41.73B 861.8M 2026-06
Roche Holding CHF 98.2B 2.5B 2026-06
Sangamo BioSciences USD 97.56M 11.39M 2025-06
Sarepta Therapeutics USD 3.19B 9.58M 2026-06
Takeda JPY 15.66T 210.16B 2026-06
TG Therapeutics USD 1.64B 110.79M 2026-06
Ultragenyx Pharmaceutical USD 1.26B 32M 2026-06
Vanda Pharmaceuticals USD 488.95M 112.19M 2025-12
Vertex Pharmaceuticals USD 27.42B 938.9M 2026-06